Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 101
Filter
1.
Arch. argent. pediatr ; 122(1): e202310061, feb. 2024. tab, ilus
Article in English, Spanish | BINACIS, LILACS | ID: biblio-1525854

ABSTRACT

El síndrome de Wiskott-Aldrich es un error innato de la inmunidad de herencia ligada al cromosoma X, producido por variantes en el gen que codifica la proteína del síndrome de Wiskott-Aldrich (WASp). Reportamos el caso clínico de un paciente de 18 meses con diagnóstico de Wiskott-Aldrich que no presentaba donante antígeno leucocitario humano (HLA) idéntico y recibió un trasplante de células progenitoras hematopoyéticas (TCPH) con donante familiar haploidéntico. La profilaxis para enfermedad de injerto contra huésped incluyó ciclofosfamida (PT-Cy). El quimerismo del día +30 fue 100 % del donante y la evaluación postrasplante de la expresión de la proteína WAS fue normal. Actualmente, a 32 meses del trasplante, presenta reconstitución hematológica e inmunológica y quimerismo completo sin evidencia de enfermedad injerto contra huésped. El TCPH haploidéntico con PT-Cy se mostró factible y seguro en este caso de síndrome de WiskottAldrich en el que no se disponía de un donante HLA idéntico.


Wiskott-Aldrich syndrome (WAS) is an X-linked genetic disorder caused by mutations in the gene that encodes the Wiskott-Aldrich syndrome protein (WASp). Here, we report the clinical case of an 18-month-old boy diagnosed with Wiskott-Aldrich syndrome, who did not have an HLA-matched related or unrelated donor and was treated successfully with a hematopoietic stem cell transplant (HSCT) from a haploidentical family donor. Graft-versus-host disease (GvHD) prophylaxis included post-transplant cyclophosphamide (PT-Cy). At day +30, the peripheral blood-nucleated cell chimerism was 100% and the WAS protein had a normal expression. Currently, at month 32 post-transplant, the patient has hematological and immune reconstitution and complete donor chimerism without evidence of GvHD. HSCT with PT-Cy was a feasible and safe option for this patient with WAS, in which an HLA matched donor was not available.


Subject(s)
Humans , Male , Infant , Wiskott-Aldrich Syndrome/diagnosis , Wiskott-Aldrich Syndrome/genetics , Wiskott-Aldrich Syndrome/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Graft vs Host Disease/etiology , Bone Marrow Transplantation/adverse effects , Cyclophosphamide
2.
Femina ; 49(12): 648-657, 2021. ilus
Article in Portuguese | LILACS | ID: biblio-1358200

ABSTRACT

O transplante de medula óssea (TMO) é um procedimento indicado para o tratamento de doenças hematológicas, que afetam muitas mulheres jovens. O aperfeiçoamento dos cuidados durante o TMO proporciona altos índices de cura e de sobrevida. No entanto, pode deixar sequelas em vários órgãos e sistemas, entre eles o sistema reprodutor e os órgãos genitais, impactando negativamente a qualidade de vida das receptoras do TMO. O objetivo desta publicação foi realizar uma revisão narrativa sobre o tema e propor um protocolo assistencial que torne acessível os cuidados relacionados à saúde sexual e reprodutiva a esse grupo especial de mulheres, baseado em dados clínicos de um ambulatório de assistência ginecológica às mulheres transplantadas no Hospital Amaral Carvalho, em Jaú, no interior de São Paulo.(AU)


Bone marrow transplantation (BMT) is indicated for the treatment of hematological diseases which affect many young women. The improvement of care during BMT procedures provides higher cure and survival rates. however, it can cause sequelae in various organs and systems, including the reproductive system and genitals, negatively impacting quality of life. The purpose of this publication is to present a narrative review related to this theme and to propose a healthcare protocol that allows sexual and reproductive care in this special group of patients, based on the clinical experience of a gynecological outpatient clinic at the Amaral Carvalho Hospital, in Jaú (SP) which specifically care for these women.(AU)


Subject(s)
Humans , Female , Postoperative Complications , Bone Marrow Transplantation/adverse effects , Clinical Protocols , Risk Factors , Immunosuppression Therapy/adverse effects , Primary Ovarian Insufficiency/physiopathology , Female Urogenital Diseases/physiopathology , Graft vs Host Disease/physiopathology
3.
Rev. bras. enferm ; 71(4): 1915-1920, Jul.-Aug. 2018. tab, graf
Article in English | LILACS, BDENF | ID: biblio-958670

ABSTRACT

ABSTRACT Objective: to identify damages resulting from incidents with the Hickman® catheter. Method: descriptive, retrospective, qualitative approach. The source of data were the notifications of incidents that occurred between January 2012 and May 2015, as well as the information available on the medical records of patients involved in incidents with the Hickman® catheter. Results: the incidents related to the Hickman® catheter with the greatest impact on patient care were obstruction, fracture and traction. All incidents caused damage to patients, in a greater or lesser degree, in the dimensions of physical damage and subjective damage. Final considerations: damage or potential risk of damage was present in all incidents analyzed. The need to revise cleaning and obstruction protocols for the maintenance of the permeability of Hickman® catheters was demonstrated.


RESUMEN Objetivo: identificar el acaecimiento de daños en incidentes relacionados con el catéter de Hickman®. Método: investigación descriptiva, retrospectiva, de abordaje cualitativo. Como fuente de datos, se utilizaron fichas de notificación de incidentes ocurridos entre enero de 2012 y mayo de 2015, además de informaciones relatadas en los prontuarios de los pacientes involucrados en los incidentes relacionados con el catéter de Hickman®. Resultados: los incidentes de impacto más importantes en la atención al paciente, relacionados con el catéter de Hickman®, fueron la obstrucción, la fractura y la tracción. Todos los incidentes generaron, en mayor o menor grado, daños a los pacientes en las dimensiones física y subjetiva. Consideraciones finales: se encontraba presente en todos los incidentes analizados, el daño en sí mismo o el riesgo potencial para el daño. Quedó en evidencia la necesidad de revisar los protocolos de lavado y bloqueo del catéter de Hickman® para el mantenimiento de su permeabilidad.


RESUMO Objetivo: identificar a ocorrência de danos nos incidentes relacionados ao cateter de Hickman®. Método: pesquisa descritiva, retrospectiva, de abordagem qualitativa. Como fonte dos dados, foram utilizadas as fichas de notificação de incidentes ocorridos entre janeiro de 2012 e maio de 2015, além de informações dos prontuários dos pacientes envolvidos com incidentes relacionados ao cateter de Hickman®. Resultados: os incidentes, relacionados ao cateter de Hickman®, de maior impacto para a assistência ao paciente foram a obstrução, fratura e tração. Todos os incidentes geraram dano aos pacientes, de maior ou menor grau, nas dimensões de dano físico e danos subjetivos. Considerações finais: dano ou risco potencial para dano esteve presente em todos os incidentes analisados. Evidenciou-se a necessidade de revisar os protocolos de lavagem e bloqueio para a manutenção da permeabilidade do cateter de Hickman®.


Subject(s)
Humans , Male , Female , Dialysis/instrumentation , Catheter-Related Infections/economics , Retrospective Studies , Risk Factors , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/methods , Cost-Benefit Analysis , Qualitative Research , Dialysis/methods , Middle Aged
4.
Rev. Hosp. Ital. B. Aires (2004) ; 37(2): 68-72, jun. 2017. ilus., tab.
Article in Spanish | LILACS | ID: biblio-1087152

ABSTRACT

La enfermedad injerto contra huésped es una entidad en la cual las células inmunológicas competentes de un tejido injertado reconocen y dañan antígenos presentes en el receptor del trasplante, que es incapaz de defenderse de ellas. Es una complicación frecuente del trasplante alogénico de médula ósea, y con menor frecuencia se produce luego de trasplantes de órganos sólidos o transfusiones de hemoderivados no irradiados. Se comunica el caso de una paciente de sexo femenino de 23 años, con leucemia linfoblástica aguda.y trasplante alogénico de médula ósea, que presentó una enfermedad injerto contra huésped con compromiso cutáneo y gastrointestinal dependiente de corticoides, con mejoría de los signos y síntomas cutáneos luego del tratamiento con infliximab y fotoféresis extracorpórea. (AU)


Graft versus host disease is an entity in which competent grafted immune cells recognize and damage tissue antigens present in the transplant recipient, who is unable to defend from them. It is one of the most serious complications in patients undergoing allogeneic bone marrow transplantation, although less frequently it may be associated with solid organ transplants or transfusions of not irradiated blood products. We report the case of a 23 year-old patient with acute lymphoblastic leukemia and allogeneic bone marrow transplantation, that presented graft versus host disease with skin and gastrointestinal involvement, dependent on corticosteroids, that showed improvement in signs and skin symptoms after treatment with infliximab and extracorporeal photopheresis. (AU)


Subject(s)
Humans , Female , Adult , Young Adult , Photopheresis , Graft vs Host Disease/drug therapy , Graft vs Host Disease/therapy , Signs and Symptoms , Transplantation, Homologous/adverse effects , Blood Transfusion , Methylprednisolone/administration & dosage , Prednisone/administration & dosage , Abdominal Pain , Ganciclovir/administration & dosage , Risk Factors , Organ Transplantation/adverse effects , Bone Marrow Transplantation/adverse effects , Tacrolimus/administration & dosage , Adrenal Cortex Hormones/adverse effects , Adrenal Cortex Hormones/therapeutic use , Cytomegalovirus Infections/diagnostic imaging , Diarrhea , Mucositis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Febrile Neutropenia , Infliximab/therapeutic use , Degloving Injuries/drug therapy , Degloving Injuries/blood , Graft vs Host Disease/etiology , Graft vs Host Disease/mortality , Immunosuppressive Agents/adverse effects , Mycophenolic Acid/administration & dosage
5.
Einstein (Säo Paulo) ; 15(2): 123-129, Apr.-June 2017. tab, graf
Article in English | LILACS | ID: biblio-891384

ABSTRACT

ABSTRACT Objective To evaluate retinal changes in patients who underwent solid organ or bone marrow transplantation. Methods A retrospective analysis of medical records of patients evaluated from February 2009 to December 2016. All patients included underwent funduscopy. Clinical and demographic data regarding transplantation and ophthalmological changes were collected. Results A total of 126 patients were analyzed; of these, 108 underwent transplantation and 18 were in the waiting list. Transplantation modalities were heart, lung, kidney, liver, pancreas, combined pancreas and kidney and bone marrow transplantation. The main pre-transplantation comorbidities were diabetes and arterial hypertension. Of the 108 transplanted patients, 82 (76%) had retinal changes. All patients who underwent pancreas or combined pancreas and kidney transplantation had diabetic retinopathy. The main retinal changes found were diabetic retinopathy, hypertensive retinopathy, retinal vascular occlusions, chorioretinal infections and central serous chorioretinopathy. Conclusion Retinal changes were either related to preexisting conditions, mainly diabetic retinopathy, or developed postoperatively as a complication of the surgical procedure, or as an infection related to the immunosuppressive status, or due to drug toxicity. These patients may present with complex ophthalmological changes and should be carefully evaluated prior to surgery and further followed by an ophthalmologist skilled in the management of diabetic retinopathy and posterior pole infections.


RESUMO Objetivo Analisar as alterações retinianas de pacientes submetidos a transplantes de órgãos sólidos ou de medula óssea. Métodos Análise de prontuário dos pacientes avaliados no período de fevereiro de 2009 a dezembro de 2016. Todos os pacientes incluídos foram submetidos à avaliação fundoscópica. Foram coletados dados demográficos e clínicos, referentes ao transplante e às alterações oftalmológicas encontradas. Resultados Foram avaliados 126 pacientes, sendo 108 submetidos a transplantes e 18 que aguardavam o procedimento. Foram avaliados pacientes submetidos a transplantes de coração, pulmão, rim, fígado, pâncreas, pâncreas-rim e medula óssea. As principais comorbidades pré-transplante foram diabetes e hipertensão arterial. Dos 108 pacientes transplantados, 82 (76%) apresentaram alterações retinianas. Todos os pacientes submetidos ao transplante de pâncreas ou pâncreas-rim apresentaram alterações retinianas relacionadas ao diabetes. As principais alterações retinianas detectadas foram retinopatia diabética, retinopatia hipertensiva, oclusões vasculares retinianas, infecções coriorretinianas e coriorretinopatia serosa central. Conclusão As alterações retinianas estavam relacionadas a doenças preexistentes, principalmente à retinopatia diabética, ou surgiram após o transplante, como complicação do procedimento cirúrgico, ou como complicação infecciosa associada à imunossupressão, ou ainda por toxicidade medicamentosa. Tais pacientes podem apresentar alterações oculares complexas, devendo ser submetidos à avaliação retiniana pré-operatória cuidadosa e ao acompanhamento pós-operatório por oftalmologista especializado no manejo da retinopatia diabética e de doenças infecciosas do segmento posterior ocular


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Postoperative Complications/etiology , Bone Marrow Transplantation/adverse effects , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Diabetic Retinopathy/ethnology , Hypertensive Retinopathy/etiology , Vitreous Hemorrhage/etiology , Retrospective Studies , Diabetes Complications/complications , Hypertension/complications , Immune Tolerance/immunology
6.
Braz. j. otorhinolaryngol. (Impr.) ; 83(1): 105-111, Jan.-Feb. 2017. tab, graf
Article in English | LILACS | ID: biblio-839408

ABSTRACT

Abstract Introduction Sinusitis is a common morbidity in general population, however little is known about its occurrence in severely immunocompromised patients undergoing allogeneic hematopoietic stem cell transplantation. Objective The aim of the study was to analyze the literature concerning sinusitis in patients undergoing allogeneic bone marrow transplantation. Methods An electronic database search was performed with the objective of identifying all original trials examining sinusitis in allogeneic hematopoietic stem cell transplant recipients. The search was limited to English-language publications. Results Twenty five studies, published between 1985 and 2015 were identified, none of them being a randomized clinical trial. They reported on 31–955 patients, discussing different issues i.e. value of pretransplant sinonasal evaluation and its impact on post-transplant morbidity and mortality, treatment, risk factors analysis. Conclusion Results from analyzed studies yielded inconsistent results. Nevertheless, some recommendations for good practice could be made. First, it seems advisable to screen all patients undergoing allogeneic hematopoietic stem cell transplantation with Computed Tomography (CT) prior to procedure. Second, patients with symptoms of sinusitis should be treated before hematopoietic stem cell transplantation (HSCT), preferably with conservative medical approach. Third, patients who have undergone hematopoietic stem cell transplantation should be monitored closely for sinusitis, especially in the early period after transplantation.


Resumo Introdução A sinusite é uma doença comum na população em geral, porém pouco se sabe sobre a sua ocorrência em pacientes gravemente imunocomprometidos submetidos a transplante alogênico de células-tronco hematopoiéticas. Objetivo O objetivo do estudo foi analisar a literatura sobre sinusite em pacientes submetidos a transplante alogênico de medula óssea. Método Uma busca na base de dados eletrônica foi realizada com o objetivo de identificar todos os artigos originais que investigaram sinusite em receptores de transplante alogênico de células-tronco hematopoiéticas. A busca foi limitada a publicações em língua inglesa. Resultados Foram identificados 25 estudos, publicados entre 1985 e 2015, sendo que nenhum deles era um ensaio clínico randomizado. Eles incluíram 31-955 pacientes, discutindo diferentes questões, ou seja, valor da avaliação sinonasal pré-transplante e seu impacto na morbidade e mortalidade pós-transplante, tratamento, análise de fatores de risco. Conclusão Os resultados dos estudos analisados produziram resultados inconsistentes. No entanto, algumas recomendações para boas práticas poderiam ser feitas. Em primeiro lugar, parece aconselhável avaliar todos os pacientes submetidos a transplante alogênico de hematopoiéticas com tomografia computadorizada (TC) antes do procedimento. Em segundo lugar, os pacientes com sintomas de sinusite devem ser tratados antes de um Transplante de Células-Tronco Hematopoiéticas (TCTH), de preferência com abordagem clínica conservadora. Em terceiro lugar, os pacientes que se submeteram a TCTH devem ser cuidadosamente monitorizados para sinusite, especialmente no período inicial após o transplante.


Subject(s)
Humans , Sinusitis/etiology , Bone Marrow Transplantation/adverse effects , Risk Factors
7.
Lima; s.n; feb. 2017.
Non-conventional in Spanish | LILACS, BRISA | ID: biblio-848411

ABSTRACT

INTRODUCCIÓN: Antecedentes: El presente dictamen expone la evaluación de tecnología de la eficacia y seguridad de posaconazil como profilaxis antifúngica en pacientes neutropénicos severos por quimioterapia de inducción o trasplante alogénico de médula ósea, con neoplasia hematológica con alto riesgo de infección fúngica invasiva. Aspectos Generales: Las infecciones fúngicas invasiva (IFI) son infecciones de tipo oportunista, las cuales son una causa principal de morbilidad y mortalidad en pacientes en condiciones críticas o inmunocomprometidos como por ejemplo aquellos en estado neutropénico recibiendo tratamiento con quimioterapia por inducción debido a malignidades hematológicas. La frencuencia y diversidad de las IFIs depende de la enfermedad de fondo, la terapia de manejo y la incidencia de la enfermedad de fondo. La aspergillosis y candidiasis son las IFIs más comunes y causantes de aproximadamente el 40 y 50% de IFIs en pacientes con neutropenia. METODOLOGÍA: Estrategia de Búsqueda: Se llevó a cabo una búsqueda sistemática de la literatura con respecto a la eficacia y seguridad de posaconazol en pacientes neutropécnicos severos por quimioterapia de inducción o trasplante alogénico de médula ósea, con neoplasia hematológica con alto riesgo de infección fúngica invasiva. para la búsqueda primaria se revisó en primer lugar la información disponible por entidades reguladoras y normativas de autorización comercial como la Administración de Drogas y Alimentos (FDA) de Estaods Unidos, la Agencia de Medicamentos Europea (EMA) y la Dirección General de Medicamentos y Drogas (DIGEMID) en el Perú. RESULTADOS: Se realizó una búsqueda para así procurar recabar toda de evidencia disponible que pueda responder a la pregunta PICO de interés: eficacia y seguridad del uso de posaconazol como profilaxis antifúngica en pacientes neutropénicos severos por quimioterapia de inducción o trasplante alogénico de médula ósea, con neoplasia hematológica con alto riesgo de infección fúngica invasiva. Se encontró que la información fue abundante, por lo que se seleccionaron sólo los estudios de mejor calidad metodológica para la descripción y evaluación de la evidencia. CONCLUSIONES: El presente dictamen expone la evaluación de la eficacia y seguridad de posaconazol como profilaxis antifúngica en pacientes hematológicos neutropénicos y alto riesgo de infecciones fúngicas invasivas. Se ha encontrado evidencia que sustenta la eficacia y seguridad del posaconazol como profilaxis antifúngica en pacientes hematológicos neutropénicos y alto riesgo de infecciones fúngicas invasivas. El Instituto de Evaluación de Tecnologías en Salud e Investigación-IETSI aprueba el uso de posaconazol como profilaxis antifúngica en pacientes hematológicos neutropénicos con alto riesgo de infecciones fúngicas invasivas. El Dictamen Preliminar tendrá una vigencia de dos años a partir de la fecha de su publicación.


Subject(s)
Humans , Antifungal Agents/administration & dosage , Invasive Fungal Infections/drug therapy , Bone Marrow Transplantation/adverse effects , Hematologic Neoplasms , Induction Chemotherapy/adverse effects , Neutropenia/blood , Technology Assessment, Biomedical , Treatment Outcome
8.
An. bras. dermatol ; 90(6): 814-821, Nov.-Dec. 2015. tab, graf
Article in English | LILACS | ID: lil-769513

ABSTRACT

Abstract: BACKGROUND: Permanent alopecia after bone marrow transplantation is rare, but more and more cases have been described, typically involving high doses of chemotherapeutic agents used in the conditioning regimen for the transplant. Busulfan, classically described in cases of irreversible alopecia, remains associated in recent cases. The pathogenesis involved in hair loss is not clear and there are few studies available. In addition to chemotherapeutic agents, another factor that has been implicated as a cause is chronic graft-versus-host disease. However, there are no histopathological criteria for defining this diagnosis yet. OBJECTIVE: the study aims to evaluate clinical and histological aspects in cases of permanent alopecia after bone marrow transplantation, identifying features of permanent alopecia induced by myeloablative chemotherapy and alopecia as a manifestation of chronic graft-versus-host disease. METHODS: data were collected from medical records of 7 patients, with description of the clinical features and review of slides and paraffin blocks of biopsies. RESULTS: Two distinct histological patterns were found: one similar to androgenetic alopecia, non-scarring pattern, and other similar to lichen planopilaris, scarring alopecia. CONCLUSION: The first pattern corroborates the literature cases of permanent alopecia induced by chemotherapeutic agents, and the second is compatible with manifestation of chronic graft-versus-host disease on scalp, that has never been described yet. The results contribute to the elucidation of the factors involved in these cases, including the development of therapeutic methods.


Subject(s)
Adult , Child , Female , Humans , Male , Middle Aged , Young Adult , Alopecia/chemically induced , Alopecia/pathology , Bone Marrow Transplantation/adverse effects , Busulfan/adverse effects , Graft vs Host Disease/complications , Myeloablative Agonists/adverse effects , Biopsy , Chronic Disease , Hair Follicle/pathology , Retrospective Studies , Scalp/pathology , Time Factors
9.
Int. braz. j. urol ; 41(6): 1126-1131, Nov.-Dec. 2015. tab
Article in English | LILACS | ID: lil-769771

ABSTRACT

Purpose: To evaluate the overall prognosis of post-stem cell transplant inpatients who required continuous bladder irrigation (CBI) for hematuria. Materials and Methods: We performed a retrospective analysis of adult stem cell transplant recipients who received CBI for de novo hemorrhagic cystitis as inpatients on the bone marrow transplant service at Washington University from 2011-2013. Patients who had a history of genitourinary malignancy and/or recent surgical urologic intervention were excluded. Multiple variables were examined for association with death. Results: Thirty-three patients met our inclusion criteria, with a mean age of 48 years (23-65). Common malignancies included acute myelogenous leukemia (17/33, 57%), acute lymphocytic leukemia (3/33, 10%), and peripheral T cell lymphoma (3/33, 10%). Median time from stem cell transplant to need for CBI was 2.5 months (0 days-6.6 years). All patients had previously undergone chemotherapy (33/33, 100%) and 14 had undergone prior radiation therapy (14/33, 42%). Twenty-eight patients had an infectious disease (28/33, 85%), most commonly BK viremia (19/33, 58%), cytomegalovirus viremia (17/33, 51%), and bacterial urinary tract infection (8/33, 24%). Twenty-two patients expired during the same admission as CBI treatment (22/33 or 67% of total patients, 22/28 or 79% of deaths), with a 30-day mortality of 52% and a 90-day mortality of 73% from the start of CBI. Conclusions: Hemorrhagic cystitis requiring CBI is a symptom of severe systemic disease in stem cell transplant patients. The need for CBI administration may be a marker for mortality risk from a variety of systemic insults, rather than directly attributable to the hematuria.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Cystitis/mortality , Cystitis/therapy , Hematopoietic Stem Cell Transplantation/mortality , Hematuria/mortality , Hematuria/therapy , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/mortality , Cystitis/etiology , Hospital Mortality , Hematopoietic Stem Cell Transplantation/adverse effects , Hematuria/etiology , Retrospective Studies , Risk Factors , Severity of Illness Index , Time Factors , Therapeutic Irrigation/methods , United States/epidemiology
10.
Med. infant ; 22(1)Marzo 2015. tab, ilus
Article in Spanish | LILACS | ID: biblio-905057

ABSTRACT

El desorden linfoproliferativo postrasplante es una de las complicaciones más importantes producidas por el virus Epstein Barr (EBV) en pacientes trasplantados de órganos sólidos y de médula ósea ya que afecta la sobrevida del paciente y del injerto. En estos pacientes se han reportado altos niveles de carga viral en sangre periférica que preceden al desarrollo del desorden linfoproliferativo postrasplante. Por esto el monitoreo de la carga viral (CV) permite detectar pacientes en riesgo a desarrollar esta patología para iniciar una terapia preventiva. El objetivo de este trabajo fue desarrollar una técnica de PCR en tiempo real cualitativa (RT PCR) que permitiera ser utilizada como prueba de tamizaje previo a la determinación de CV EBV. De esta manera se podrían minimizar el costo que implicaría la utilización de un método cuantitativo comercial para todas las muestras que ingresaran al monitoreo viral. Teniendo en cuenta el desempeño de la RT PCR desarrollada, se estableció Ct ≤ 37 como valor límite para evitar amplificación inespecífica y seleccionar las muestras candidatas a la determinación de CV EBV. Dicho punto de corte presentó una sensibilidad diagnóstica relativa de 80%, una especificidad diagnóstica relativa de 85%, un valor predictivo positivo (VPP) de 53% y un valor predictivo negativo (VPN) de 95%. Para ello se consideró que valores de CV EBV< 4000 copias/ml sangre eran bajas o no presentaban riesgo de desarrollar complicaciones. El límite de detección LoD 95% fue de 280 copias de EBV/ml sangre (66 ­ 1184, IC 95%). Esta técnica demostró tener una buena performance analítica, ser de fácil implementación y el punto de corte seleccionado nos permitió realizar un buen tamizaje de muestras de pacientes trasplantados que resultaban ser candidatas a la determinación de CV, con la consiguiente disminución de costos (AU)


Post-transplant lymphoproliferative disorder is one of the main complications caused by the Epstein Barr virus (EBV) in solidorgan and bone-marrow transplantation patients affecting survival of both the patient and the graft. High levels of viral load (VL) in peripheral blood preceding the development of posttransplant lymphoproliferative disorder have been reported in these patients. Therefore, VL monitoring allows detection of patients who are at risk of developing this disease to start preventive treatment. The aim of this study was to develop a qualitative real-time PCR technique to use as an early screening test to determine EBV VL. This test may minimize costs related to the use of a commercial quantitative method for all the samples that enter for viral screening. Considering the performance of the RT PCR method developed, a Ct ≤ 37 was established as the cut-off limit to avoid unspecific amplification and select the samples that are candidates for EBV VL determination. This cut-off point had a relative diagnostic sensitivity of 80%, a relative diagnostic specificity of 85%, a positive predictive value (PPV) of 53% and a negative predictive value (NPV) of 95%. Thus, an EBV VL< 4000 copies/ml blood was considered to be low and not to be a risk for developing complications. The 95% limit of detection was 280 copies of EBV/ml blood (66­1184, 95%CI). The technique showed to be of good analytical performance and easy implementation. The cut-off point allowed a good screening of the samples of transplanted patients to detect those who are candidates for VL determination at a lower cost (AU)


Subject(s)
Humans , Epstein-Barr Virus Infections/diagnosis , Epstein-Barr Virus Infections/virology , Lymphoproliferative Disorders/etiology , Polymerase Chain Reaction/methods , Viral Load , Bone Marrow Transplantation/adverse effects , Lymphoproliferative Disorders/prevention & control , Organ Transplantation/adverse effects
11.
J. coloproctol. (Rio J., Impr.) ; 35(1): 46-52, Jan-Mar/2015. ilus
Article in English | LILACS | ID: lil-745963

ABSTRACT

BACKGROUND: Human bone marrow transplantation (BMT) becomes an accepted treatment of leukemia, aplastic anemia, immunodeficiency syndromes, and hematologic malignancies. Colorectal surgeons must know how to determine and manage the main colonic complications. OBJECTIVE: To review the clinical features, clinical and pathological staging of graft vs host disease (GVHD), and treatment of patients suffering with colonic complications of human bone marrow transplantation. PATIENTS AND METHODS: We have reviewed the records of all patients that received an allogeneic bone marrow transplant and were evaluated at our Colon and Rectal Surgery department due to gastrointestinal symptoms, between January 2007 and January 2012. The study was carried out in patients who developed colonic complications, all of them with clinical, histopathological or laboratory diagnosis. RESULTS: The study group was constituted by 77 patients, 43 male and 34 female patients. We identified colonic complications in 30 patients (38.9%); five patients developed intestinal toxicity due to pretransplant chemotherapy (6.4%); graft vs. host disease was present in 16 patients (20%); 13 patients (16.8%) developed acute colonic GVHD, and 3 (3.8%) chronic GVHD. Infection was identified in 9 patients (11.6%). CONCLUSIONS: The three principal colonic complications are the chemotherapy toxicity, GVHD, and superinfection; the onset of symptoms could help to suspect the type of complication (0-20 day chemotherapy toxicity, 20 and more GVHD), and infection could appear in any time of transplantation. (AU)


EXPERIÊNCIA: O transplante de medula óssea humana (MOH) passou a ser um tratamento adotado para leucemia, anemia aplástica, síndromes de imunodeficiência e neoplasias hematológicas. Cirurgiões colorretais devem saber como determinar e tratar as principais complicações do cólon. OBJETIVO: Revisar as características clínicas, estadiamentos clínico e patológico da doença do enxerto versus hospedeiro (DEVH) e o tratamento de pacientes padecendo com as complicações colônicas do transplante de medula óssea humana. PACIENTES E MÉTODOS: Revisamos os registros de todos os pacientes que receberam um transplante de medula óssea alogênica e foram avaliados em nosso Departamento de Cirurgia do Cólon e Reto em função de sintomas gastrointestinais, entre janeiro de 2007 e janeiro de 2012. O estudo teve por base os pacientes que desenvolveram complicações do cólon, todos com diagnóstico clínico, histopatológico ou laboratorial. RESULTADOS: O grupo de estudo foi constituído por 77 pacientes, sendo 43 homens e 34 mulheres. Identificamos complicações do cólon em 30 pacientes (38,9%); cinco pacientes exibiam toxicidade intestinal por quimioterapia antes do transplante (6,4%); DEVH estava presente em 16 pacientes (20%), 13 pacientes (16,8%) foram acometidos por DEVH colônica aguda três pacientes (3,8%) DEVH crônica. Infecção foi detectada em 9 pacientes (11,6%). CONCLUSÕES: As três principais complicações do cólon são: toxicidade por quimioterapia, DEVH e superinfecção. O surgimento dos sintomas poderia ajudar a levantar suspeitas sobre o tipo de complicação (0-20 dias, toxicidade por quimioterapia; 20 ou mais dias, DEVH). Infecções podem ocorrer em qualquer momento do transplante. (AU)


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Bone Marrow Transplantation/adverse effects , Graft vs Host Disease/etiology , Colonoscopy , Colitis/etiology , Colon/pathology , Transplantation Conditioning/adverse effects , Enterocolitis/etiology
12.
Braz. j. infect. dis ; 19(1): 90-93, Jan-Feb/2015. graf
Article in English | LILACS | ID: lil-741230

ABSTRACT

Disseminated infection by Fusarium is a rare, frequently lethal condition in severely immunocompromised patients, including bone marrow transplant recipients. However, autologous bone marrow transplant recipients are not expected to be at high risk to develop fusariosis. We report a rare case of lethal disseminated Fusarium infection in an autologous bone marrow transplant recipient during pre-engraftment phase.


Subject(s)
Humans , Male , Middle Aged , Bone Marrow Transplantation/adverse effects , Fusariosis/pathology , Lymphoma, Follicular/surgery , Fusariosis/diagnosis , Immunocompromised Host , Transplantation, Autologous
13.
Rev. cuba. ortop. traumatol ; 28(2): 181-192, jul.-dic. 2014. ilus, tab
Article in Spanish | LILACS, CUMED | ID: lil-740946

ABSTRACT

INTRODUCCIÓN: se realizó el trasplante de células madre en siete pacientes diagnosticados con enfermedad degenerativa de un solo disco intervertebral. OBJETIVO: evaluar la seguridad del proceder y la tolerancia a las células trasplantadas. MÉTODOS: las células fueron extraídas de medula ósea del propio paciente, aisladas por el método de Ficoll-Hypaque e implantadas en los discos seleccionados como grados II y III de la clasificación de Pfirrmann por imágenes de resonancia. Se evaluaron los resultados al año del injerto. RESULTADOS: no se registraron eventos adversos importantes derivados del procedimiento ni del injerto de células. Con la utilización del índice de Oswestry se evaluaron los resultados clínicos como beneficiosos, así como la posible mejoría en las imágenes de resonancia magnética antes y un año después. CONCLUSIÓN: los resultados demuestran que las células madre obtenidas de médula ósea del propio paciente pueden ser trasplantadas de manera segura, con excelente tolerancia y sin complicaciones usando el método descrito.


INTRODUCTION: stem cell transplant was performed in seven patients diagnosed with degenerative one intervertebral disc. OBJECTIVE: evaluate the safety and tolerance of the procedure to transplanted cells. METHODS: cells were extracted from the patient's own bone marrow. They were isolated by the Ficoll-Hypaque method and they were implemented in discs selected as grades II and III according to Pfirrmann classification resonance imaging. Graft outcomes were evaluated one year later. RESULTS: no significant adverse events were recorded from the procedure or graft cells. By using the Oswestry index, clinical outcomes were evaluated as beneficial, as well as the possible improvement in images from magnetic resonance imaging before and a year later. CONCLUSION: these results show that stem cells derived from the patient's own bone marrow can be safely transplanted with excellent tolerance and no complications using the method described.


INTRODUCTION: une greffe de cellules souches a été réalisée chez sept patients diagnostiqués de maladie dégénérative sur un seul disque intervertébral. OBJECTIF: le but de cette étude est d'évaluer cette procédure et la tolérance aux cellules transplantées. MÉTHODES: les cellules proviennent de la moelle osseuse du patient lui-même, isolées par la méthode de Ficoll-Hypaque et implantées au niveau des disques en grade II et III selon classification RM de Pfirrmann. Les résultats ont été évalués un an après la transplantation. RÉSULTATS: il n'y a pas eu de complications importantes au cours de l'opération ni de la greffe de cellules. Au moyen de l'indice d'Oswestry, les résultats cliniques ont été classifiés de bons ; une amélioration potentielle des images par RM a été aussi remarquée avant et après un an. CONCLUSIONS: les résultats montrent que les cellules souches prélevées de la moelle osseuse du propre patient peuvent être transplantées de manière sure, avec une tolérance excellente, et sans complications, en utilisant la méthode décrite.


Subject(s)
Humans , Male , Female , Middle Aged , Magnetic Resonance Imaging/statistics & numerical data , Bone Marrow Transplantation/adverse effects , Stem Cell Transplantation/adverse effects , Intervertebral Disc Degeneration/diagnosis , Prospective Studies
14.
Arq. bras. endocrinol. metab ; 58(5): 484-492, 07/2014. tab, graf
Article in English | LILACS | ID: lil-719207

ABSTRACT

Organ transplantation is the gold standard therapy for several end-stage diseases. Bone loss is a common complication that occurs in transplant recipients. Osteoporosis and fragility fractures are serious complication, mainly in the first year post transplantation. Many factors contribute to the pathogenesis of bone disease following organ transplantation. This review address the mechanisms of bone loss including the contribution of the immunosuppressive agents as well as the specific features to bone loss after kidney, lung, liver, cardiac and bone marrow transplantation. Prevention and management of bone loss in the transplant recipient should be included in their post transplant follow-up in order to prevent fractures.


Transplantes de órgão é terapia padrão-ouro para várias doenças em estágio terminal. Perda óssea é uma complicação comum que ocorre em pacientes transplantados. Osteoporose e fraturas por fragilidade são complicações sérias, principalmente no primeiro ano pós-transplante. Muitos fatores podem contribuir para patogênese da doença óssea nesses pacientes. Esta revisão aborda os mecanismos de perda óssea incluindo o papel dos agentes imunossupressores, bem como os fatores específicos da perda óssea após rim, pulmão, fígado, coração e transplante de medula óssea. A prevenção e o tratamento da perda óssea nos pacientes transplantados devem ser realizados para evitar fraturas.


Subject(s)
Humans , Bone Diseases/etiology , Bone Diseases/prevention & control , Bone Resorption/etiology , Immunosuppressive Agents/adverse effects , Osteoporotic Fractures/etiology , Transplantation/adverse effects , Bone Marrow Transplantation/adverse effects , Calcium/blood , Diphosphonates/therapeutic use , Heart Transplantation/adverse effects , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Lung Transplantation/adverse effects , Vitamin D/therapeutic use
15.
Med. infant ; 21(1): 28-31, mar. 2014. tab
Article in Spanish | LILACS | ID: lil-774896

ABSTRACT

Objetivo: Describir y analizar las infecciones del sistema nervioso entral (SNC ) en una cohorte de pacientes pediátricos eceptores de trasplante de células progenitoras hematopoyéticas TCPH). Pacientes y métodos: Estudio descriptivo, etrospectivo de cohorte. Se incluyeron pacientes trasplantados ntre 1994 y 2012. Se registraron sus características generales, tipo de trasplante y fuente de células progenitoras hematopoyéticas (CPH), momento de presentación de la infección, relación de la misma con el periodo de neutropenia, enfermedad de injerto contra huésped (EICH) aguda o crónica, el tratamiento recibido y la evolución posterior. Resultados: se registraron 12 casos de infección del SNC que representa un 3,3% sobre el total de TCPH. El 75% fueron varones y la mediana de edad fue 11 años (rango 1-16). El 25% de los casos eran receptores de TCPH no familiares. La fuente de CPH fue médula ósea (MO) en el 58%, sangre de cordón umbilical (SCU) en el 33% y sangre periférica (SP) en el 9%. La etiología más frecuente (58%) fue viral (Herpes simple, Herpes 6, CMV, Varicela zoster, JC y enterovirus) seguida por las infecciones fúngicas (25%), principalmente por Aspergillus spp. e Histoplasmosis, y el compromiso del SNC por Toxoplasma gondii (17%). Cinco pacientes fallecieron a causa de la infección del SNC y solo tres sobrevivieron a largo plazo. Se encontró una fuerte asociación entre infección del SNC y el uso de SCU como fuente de CPH (SCU 18%, MO 0,7%, SP 2,8% p< 0,01) y una tendencia a un mayor número de infecciones del SNC en los receptores de TCPH no familiares respecto a los receptores de TCPH familiares (8,1% vs 2,1% p 0,06). Conclusión: Las infecciones del SNC son una complicación poco frecuente pero muy grave del TCPH. Su sospecha debe inducir a realizar rápidamente de estudios de imágenes, del LCR y, de ser necesario, otros estudios invasivos como biopsia cerebral.


Aim: To describe and analyze infections of the central nervous system (CNS) in a cohort of pediatric patients who underwent hematopoietic stem cell transplantation (HSCT). Patients and methods: A retrospective, descriptive cohort study was conduc-ted. Patients who underwent HSCT between 1994 and 2012 were included. General features, type of transplant and sour-ce of hematopoietic stem cells (HSC), onset of the infection, association between onset of infection and duration of neu-tropenia, acute or chronic graft-versus-host disease (GVHD), treatment, and outcome were recorded. Univariate analysis of the association with acute or chronic GVHD, type of transplant, ! " # !$ CNS infection - 3.3% of all HSCT - were registered. Median age of the patients was 11 years (range 1-16) and 75% were...


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Hematopoietic Stem Cells , Central Nervous System Infections/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Bone Marrow Transplantation/adverse effects , Argentina
16.
Arq. odontol ; 50(01): 20-27, 2014. ilus
Article in Portuguese | LILACS, BBO | ID: biblio-850163

ABSTRACT

O linfoma é uma neoplasia malígna que se desenvolve nos gânglios linfáticos e uma possível abordagem terapêutica para esta doença é o transplante de medula óssea. Sob condições de imunossupressão, todo foco infeccioso pode ser ativado e, em função disto, toda infecção ativa em pacientes pré-transplantes de células hematopoiéticas deve ser erradicada previamente, para prevenir ou reduzir riscos de complicações sistêmicasnestes pacientes. Objetivo: Relatar um caso de atendimento odontológico a um paciente com necessidade premente de transplante de células tronco-hematopoiéticas, acometido de Linfoma não-Hodgkin.


Subject(s)
Humans , Male , Female , Dental Care , Lymphoma, Non-Hodgkin/complications , Bone Marrow Transplantation/adverse effects , Patient Care/trends , Root Resorption/therapy
17.
An. bras. dermatol ; 88(5): 799-802, out. 2013. graf
Article in English | LILACS | ID: lil-689725

ABSTRACT

Graft-versus-host disease is observed mainly in recipients of hematopoietic cell transplantation and is expressed by cutaneous or systemic signals and symptoms. Graft-versus-host disease is clinically classified as acute or chronic. Chronic Graft-versus-host disease occurs in up to 70% of hematopoietic cell transplanted patients and its clinical manifestations have important impact on morbidity and quality of life. The authors report an expressive cutaneous, oral and adnexal involvement in a patient with chronic Graft-versus-host disease with multiple lesions of lichenoid and atrophic pattern.


Doença enxerto contra hospedeiro é observada principalmente em pacientes transplantados de células de origem hematopoiéticas e se expressa por sinais e sintomas cutâneos ou sistêmicos. Clinicamente, a Doença enxerto contra hospedeiro é classificada em aguda ou crônica. As do tipo crônico ocorrem em até 70% dos pacientes e suas manifestações têm impacto importante na morbidade e na qualidade de vida. Os autores relatam caso com extenso comprometimento cutâneo, oral e de anexos cutâneos em paciente com Doença enxerto contra hospedeiro crônica expressa por inúmeras lesões de padrão liquenóide e de atrofia cutânea.


Subject(s)
Humans , Male , Middle Aged , Graft vs Host Disease/pathology , Lichenoid Eruptions/pathology , Skin/pathology , Atrophy , Bone Marrow Transplantation/adverse effects , Chronic Disease
18.
Rev. GASTROHNUP ; 13(3, Supl.1): S13-S16, sept.-dic. 2011.
Article in Spanish | LILACS | ID: lil-645153

ABSTRACT

La enfermedad injerto contra huésped, generalmente ocurre luego del trasplante de médula ósea alogénico.Puede ser aguda, en dos fases, aferente y eferente; y crónica, que semeja una enfermedad autoinmune. Lasmanifestaciones clínicas más frecuentes son enterocólicas. La prevención es la clave del tratamiento. Su evolución depende de la severidad de las lesiones. El soporte nutricional comprende el aporte adecuado deenergía, macro y micronutrimentos y la interacción fármaco nutrimento. Los beneficios de la inmunonutrición incluyen la disminución del riesgo de infección, el menor tiempo de estancia hospitalaria, y en cuidados intensivos.


Graft versus host disease, usually occurs after bone marrow trasnplantation, allgeneic. It may be acute, intwo phases, afferent and efferent, and chronic, which resembles an autoinmune disease. The most frequentclinical manifestations are enterocolic. Prevention is the key to treatment. Its evolution depends on the severity of injuries. Nutritional support includes adequate intake of energy, macro and micronutrients and nutrient drug interaction. Immunonutrition benefits include reduced risk of infecion, shorter hospital stay, and intensive care.


Subject(s)
Humans , Male , Female , Child , Graft vs Host Disease/epidemiology , Graft vs Host Disease/drug therapy , Graft vs Host Disease , Bone Marrow Transplantation , Bone Marrow Transplantation/adverse effects , Child Nutrition , Cyclosporine/administration & dosage , Cyclosporine/classification , Cyclosporine/pharmacology , Cyclosporine
19.
Arq. bras. cardiol ; 97(5): 420-426, nov. 2011. ilus, graf, tab
Article in Portuguese | LILACS | ID: lil-608937

ABSTRACT

FUNDAMENTO: A injeção de células-tronco no contexto do infarto agudo do miocárdio (IAM) tem sido testada quase exclusivamente pela via anterógrada intra-arterial coronariana (IAC). A via retrógrada intravenosa coronariana (IVC) pode ser uma via adicional. OBJETIVO: Comparar o padrão de distribuição e retenção celular nas vias anterógrada e retrógrada. Investigar o papel da obstrução microvascular pela ressonância magnética na retenção de células pelo tecido cardíaco após a injeção de células mononucleares da medula óssea (CMMO) no IAM. MÉTODOS: Estudo prospectivo, aberto, randomizado. Foram incluídos pacientes com IAM que apresentassem: (1) reperfusão mecânica ou química com sucesso em até 24 horas do início dos sintomas e (2) infarto acometendo mais de 10 por cento da área do ventrículo esquerdo (VE) pela cintilografia miocárdica. Cem milhões de CMMO foram injetadas na artéria relacionada ao infarto pela via IAC ou veia, pela via IVC. Um por cento das células injetadas foi marcado com Tc99m-hexametil-propileno-amina-oxima(99mTc-HMPAO). A distribuição das células foi avaliada 4 e 24 horas após a injeção da cintilografia miocárdica. Ressonância magnética cardíaca foi realizada antes da injeção de células. RESULTADOS: Trinta pacientes foram distribuídos aleatoriamente em três grupos. Não houve eventos adversos graves relacionados ao procedimento. A retenção precoce e tardia das células marcadas foi maior no grupo IAC do que no grupo IVC, independentemente da presença de obstrução da microcirculação. CONCLUSÃO: A injeção pela abordagem retrógrada mostrou-se viável e segura. A retenção de células pelo tecido cardíaco foi maior pela via anterógrada. Mais estudos são necessários para confirmar esses achados.


BACKGROUND: The injection of stem cells in the context of acute myocardial infarction (AMI) has been tested almost exclusively by anterograde intra-arterial coronary (IAC) delivery. The retrograde intravenous coronary (IVC) delivery may be an additional route. OBJECTIVE: To compare the cell distribution and retention pattern in the anterograde and retrograde routes. To investigate the role of microvascular obstruction by magnetic resonance imaging in cell retention by cardiac tissue after the injection of bone marrow mononuclear cells (BMMC) in AMI. METHODS: This was a prospective, open label, randomized study. Patients with AMI who presented: (1) successful chemical or mechanical reperfusion within 24 hours of symptom onset and (2) infarction involving more than 10 percent of the left ventricle (LV) at the myocardial scintigraphy were included in the study. One hundred million BMMC were injected into the infarction-related artery through IAC route, or vein through the IVC route. One percent of the injected cells were labeled with 99mTc-hexamethyl-propylene-amine-oxime (99mTc-HMPAO). Cell distribution was evaluated at 4 and 24 hours after the myocardial scintigraphy injection. Cardiac magnetic resonance imaging was performed before cell injection. RESULTS: Thirty patients were randomized into three groups. There were no serious adverse events related to the procedure. The early and late retention of labeled cells was higher in the IAC group than in IVC group, regardless of the presence of microcirculation obstruction. CONCLUSION: The injection using the retrograde approach was feasible and safe. Cell retention by cardiac tissue was higher using the anterograde approach. More studies are needed to confirm these findings.


Subject(s)
Female , Humans , Male , Middle Aged , Bone Marrow Transplantation/methods , Coronary Vessels/physiopathology , Microcirculation/physiology , Myocardial Infarction/surgery , Stem Cell Transplantation/methods , Bone Marrow Transplantation/adverse effects , Coronary Vessels , Injections, Intra-Arterial/methods , Myocardial Infarction/physiopathology , Myocardial Infarction , Prospective Studies , Radiopharmaceuticals , Statistics, Nonparametric , Stem Cell Transplantation/adverse effects
20.
Arq. bras. cardiol ; 96(4): 325-331, abr. 2011. ilus, tab
Article in Portuguese | LILACS | ID: lil-585914

ABSTRACT

FUNDAMENTO: Insuficiência cardíaca (IC) causada por Doença de Chagas (DC) é uma cardiomiopatia inflamatória progressiva que afeta milhões de pessoas na América Latina. Estudos com modelos de camundongo de IC devido à DC indicam que o transplante de células mononucleares derivadas da medula óssea (TCDMO) pode reduzir a inflamação, fibrose e melhorar a função miocárdica. OBJETIVO: O propósito desse estudo foi avaliar, pela primeira vez em seres humanos, a segurança e a eficácia de TCDMO no miocárdio de pacientes com IC devido à DC. MÉTODOS: Um total de 28 pacientes com IC devido à DC (média de idade de 52,2 ± 9,9 anos) com classe funcional NYHA III e IV foram submetidos à TCDMO através de injeção coronariana. Os efeitos na fração de ejeção do ventrículo esquerdo (FEVE), capacidade funcional, qualidade de vida, arritmias e parâmetros bioquímicos, imunológicos e neuro-humorais foram avaliados. RESULTADOS: Não houve complicações diretamente relacionadas ao procedimento. A FEVE foi 20,1 ± 6,8 por cento e 28,3 ± 7,9 por cento, p < 0,03 a nível basal e 180 dias após o procedimento, respectivamente. No mesmo período, melhoras significantes foram observadas na classe funcional NYHA (3,1 ± 0,3 para 1,8 ± 0,5; p < 0,001), qualidade de vida (50,9 ± 11,7 para 25,1 ± 15,9; p < 0,001), e no teste de caminhada de seis minutos (355 ± 136 m para 437 ± 94 m; p < 0,01). Não houve alterações nos marcadores de ativação imune ou neurohormonais. Nenhuma complicação foi registrada. CONCLUSÃO: Nossos dados sugerem que a injeção intracoronariana de células derivadas da medula óssea é segura e potencialmente efetiva em pacientes com IC devido à DC. A extensão do benefício, entretanto, parece ser discreta e precisa ser confirmada em estudos clínicos maiores, randomizados, duplo-cegos, controlados com placebo.


BACKGROUND: Heart failure due to Chagas' disease (HFCD) is a progressive inflammatory cardiomyopathy that affects millions of individuals in Latin America. Studies using mice models of HFCD indicate that bone marrow mononuclear cell transplantation (BMCT) may reduce inflammation, fibrosis, and improve myocardial function. OBJECTIVE: The purpose of this study was to evaluate, for the first time in humans, the safety and efficacy of BMCT to the myocardium of patients with HFCD. METHODS: A total of 28 HFCD patients (mean age 52.2 ± 9.9 years) with NYHA class III and IV were submitted to BMCT through intracoronary injection. Effects on the left ventricle ejection fraction (LVEF), functional capacity, quality-of-life, arrhythmias, biochemical, immunological, and neuro-humoral parameters, were evaluated. RESULTS: There were no complications directly related to the procedure. LVEF was 20.1 ± 6.8 percent and 28.3 ± 7.9 percent, p < 0.03 at baseline and 180 days after the procedure, respectively. In the same period, significant improvements were observed in the NYHA class (3.1 ± 0.3 to 1.8 ± 0.5; p < 0.001), quality-of-life (50.9 ± 11.7 to 25.1 ± 15.9; p < 0.001), and in the six-minute walking test (355 ± 136 m to 437 ± 94 m; p < 0,01). There were no changes in markers of immune or neurohormonal activation. No complications were registered. CONCLUSION: Our data suggest that the intracoronary injection of BMCT is safe and potentially effective in patients with HFCD. The extent of the benefit, however, appears to be small and needs to be confirmed in a larger randomized, double blind, placebo controlled clinical trial.


FUNDAMENTO: La insuficiencia cardíaca (IC), causada por la enfermedad de Chagas (EC), es una cardiomiopatía inflamatoria progresiva que afecta a millones de personas en Latinoamérica. Estudios con modelos experimentales de IC en razón de la EC, nos indican que el transplante de células mononucleares derivadas de la médula ósea (TCMO), puede reducir la inflamación y la fibrosis, mejorando así la función miocárdica. OBJETIVO:El objetivo de este estudio fue evaluar, por primera vez en seres humanos, la seguridad y la eficacia del TCMO en el miocardio de pacientes con IC debido a la EC. MÉTODOS:Fueron estudiados un total de 28 pacientes con IC debido a la EC (con edad promedio 52,2 ± 9,9 años), en clases funcionales III y IV (NYHA), al TCMO por medio de una inyección coronaria. Se evaluaron los efectos en la fracción de eyección del ventrículo izquierdo (FEVI), capacidad funcional, calidad de vida, arritmias y parámetros bioquímicos, inmunológicos y neurohumorales. RESULTADOS:No se registraron complicaciones relacionadas directamente con el procedimiento. La FEVI pasó de 20,1 ± 6,8 por ciento para 28,3 ± 7,9 por ciento, p < 0,03, cuando se comparó con el período basal y 180 días después del procedimiento, respectivamente. En el mismo período, también se observaron mejorías en la clase funcional NYHA promedio (3,1 ± 0,3 para 1,8 ± 0,5; p < 0,001), puntuación de calidad de vida de Minnesota (50,9 ± 11,7 para 25,1 ± 15,9; p < 0,001), y en el test de esfuerzo de seis minutos (355 ± 136 m para 437 ± 94 m; p < 0,01). No hubo alteraciones en los marcadores de activación inflamatoria o neurohormonales. Ninguna complicación fue registrada. CONCLUSIÓN:Nuestros datos sugieren que la inyección intracoronaria de las células derivadas de la médula ósea es segura y potencialmente efectiva en pacientes con IC debido a la EC. La extensión del beneficio, sin embargo, parece ser discreta, y necesita ser confirmada en los ensayos clínicos randomizados, doble ciegos, controlados con placebo.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Bone Marrow Transplantation , Chagas Cardiomyopathy/surgery , Heart Failure/surgery , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/immunology , Chagas Cardiomyopathy/complications , Fluoroimmunoassay , Gelatinases/analysis , Heart Failure/etiology , Monokines/analysis , Quality of Life , Stroke Volume/physiology , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL